Grifols SA
GRFSGrifols, S.A. (Catalan: ) is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Drugs in Pipeline
44
Phase 3 Programs
23
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 2 past
Xembify
Hypogammaglobulinemia
Liquid Alpha₁-PI
Alpha₁-Antitrypsin Deficiency
Alpha-1 MP
Alpha 1-Antitrypsin Deficiency
Albutein 20%
Decompensated Cirrhosis and Ascites
alpha-1 proteinase inhibitor (human)
Alpha 1-Antitrypsin Deficiency
Fibrin Sealant (FS) Grifols
Soft Tissue Surgical Bleeding
IVIG-PEG
Primary Immunodeficiency
Fibrin Sealant Grifols
Excessive Bleeding During Surgery
Specific intravenous anti-hepatitis B immunoglobulin
Hepatitis B, Chronic
IGIV3I Grifols
Immune (Idiopathic) Thrombocytopenic Purpura
GAMUNEX-C
COVID-19
Alpha-1 15%
Alpha1-Antitrypsin Deficiency
Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Albumin 5%
Alzheimer's Disease
IGIV3I Grifols 10%
Idiopathic Thrombocytopenic Purpura
FS Grifols
Target Bleeding Site During Peripheral Vascular Surgery
Hepatitis B immune globulin
Hepatitis B
Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
Immunologic Deficiency Syndrome
IGSC 20%
Primary Immunodeficiency
Plasma-derived AT-III concentrate
Antithrombin III Deficiency
IGIV-C 10%
Primary Immunodeficiency
IGIV-C
Myasthenia Gravis, Generalized
Gamunex-C, 10% Injectable Solution
Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Immune Globulin Intravenous (Human)
Immunologic Deficiency Syndrome
Convalescent anti-SARS-CoV-2 MBT Plasma
COVID-19
Prolastin-C, 60 mg/kg
Emphysema
GRF312 5%
Dry Eye Disease
Prolastin
COVID-19
Human thrombin
Hemostasis
Alpha1-Proteinase Inhibitor (Human)
Cystic Fibrosis
Antithrombin III
Acquired Antithrombin III Deficiency
BeneFIX
Hemophilia B
Albumin (Human) 20%, United States Pharmacopeia (USP)
Alpha 1-Antitrypsin Deficiency
Plasmin
Acute Peripheral Arterial Occlusion
Alpha-1 HC 100 mg
Cystic Fibrosis
Albutein 5%
Alzheimer's Disease
Intravenous Immune Globulin
COVID-19
Albumin
Amyotrophic Lateral Sclerosis
Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Purpura, Thrombocytopenic, Idiopathic
Albumin (Human) 25%, United States Pharmacopeia (USP)
Multiple Sclerosis, Relapsing-Remitting
Plasmin (Human)
Acute Ischemic Stroke
Human Plasma-Derived Fibrinogen Concentrate
Congenital Afibrinogenemia
intramuscular hepatitis B virus immune globulin
Hepatitis B, Chronic
AT-III (Human)
Cardiac Surgery
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Xembify | Phase 3 | Hypogammaglobulinemia | - | - |
Liquid Alpha₁-PI | Phase 3 | Alpha₁-Antitrypsin Deficiency | - | - |
Alpha-1 MP | Phase 3 | Alpha 1-Antitrypsin Deficiency | - | - |
Albutein 20% | Phase 3 | Decompensated Cirrhosis and Ascites | - | - |
alpha-1 proteinase inhibitor (human) | Phase 3 | Alpha 1-Antitrypsin Deficiency | - | - |
Fibrin Sealant (FS) Grifols | Phase 3 | Soft Tissue Surgical Bleeding | - | - |
IVIG-PEG | Phase 3 | Primary Immunodeficiency | - | - |
Fibrin Sealant Grifols | Phase 3 | Excessive Bleeding During Surgery | - | - |
Specific intravenous anti-hepatitis B immunoglobulin | Phase 3 | Hepatitis B, Chronic | - | - |
IGIV3I Grifols | Phase 3 | Immune (Idiopathic) Thrombocytopenic Purpura | - | - |
GAMUNEX-C | Phase 3 | COVID-19 | - | - |
Alpha-1 15% | Phase 3 | Alpha1-Antitrypsin Deficiency | - | - |
Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified | Phase 3 | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | - | - |
Albumin 5% | Phase 3 | Alzheimer's Disease | - | - |
IGIV3I Grifols 10% | Phase 3 | Idiopathic Thrombocytopenic Purpura | - | - |
FS Grifols | Phase 3 | Target Bleeding Site During Peripheral Vascular Surgery | - | - |
Hepatitis B immune globulin | Phase 3 | Hepatitis B | - | - |
Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified | Phase 3 | Immunologic Deficiency Syndrome | - | - |
IGSC 20% | Phase 3 | Primary Immunodeficiency | - | - |
Plasma-derived AT-III concentrate | Phase 3 | Antithrombin III Deficiency | - | - |
IGIV-C 10% | Phase 3 | Primary Immunodeficiency | - | - |
IGIV-C | Phase 3 | Myasthenia Gravis, Generalized | - | - |
Gamunex-C, 10% Injectable Solution | Phase 3 | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | - | - |
Immune Globulin Intravenous (Human) | Phase 2 | Immunologic Deficiency Syndrome | - | - |
Convalescent anti-SARS-CoV-2 MBT Plasma | Phase 2 | COVID-19 | - | - |
Prolastin-C, 60 mg/kg | Phase 2 | Emphysema | - | - |
GRF312 5% | Phase 2 | Dry Eye Disease | - | - |
Prolastin | Phase 2 | COVID-19 | - | - |
Human thrombin | Phase 2 | Hemostasis | - | - |
Alpha1-Proteinase Inhibitor (Human) | Phase 2 | Cystic Fibrosis | - | - |
Antithrombin III | Phase 2 | Acquired Antithrombin III Deficiency | - | - |
BeneFIX | Phase 2 | Hemophilia B | - | - |
Albumin (Human) 20%, United States Pharmacopeia (USP) | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
Plasmin | Phase 2 | Acute Peripheral Arterial Occlusion | - | - |
Alpha-1 HC 100 mg | Phase 2 | Cystic Fibrosis | - | - |
Albutein 5% | Phase 2 | Alzheimer's Disease | - | - |
Intravenous Immune Globulin | Phase 2 | COVID-19 | - | - |
Albumin | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified | Phase 2 | Purpura, Thrombocytopenic, Idiopathic | - | - |
Albumin (Human) 25%, United States Pharmacopeia (USP) | Phase 2 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Plasmin (Human) | Phase 2 | Acute Ischemic Stroke | - | - |
Human Plasma-Derived Fibrinogen Concentrate | Phase 2 | Congenital Afibrinogenemia | - | - |
intramuscular hepatitis B virus immune globulin | Phase 2 | Hepatitis B, Chronic | - | - |
AT-III (Human) | Phase 2 | Cardiac Surgery | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Grifols SA's drug pipeline?→
CatalystAlert tracks 44 drug candidates in Grifols SA's (GRFS) pipeline across Phase 3, Phase 2. Its lead program is Xembify (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Grifols SA's next FDA catalyst?→
Grifols SA's (GRFS) next tracked catalyst is a Earnings expected July 27, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GRFS biotech catalysts?→
Add GRFS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Grifols SA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.